Hatice Bölek

MD | Medical Oncologist | Alumni @Hacettepe1967 @AnkaraUni | 2024 ASCO IDEA awardee | #cat lover

[Hatice Bölek @hatice_bolek]

Our review on DDIs in prostate Ca is now published @ESMO_Open! @coskunyazgann

Thanks to @DrYukselUrun @Silke_Gillessen @DrRanaMcKay @yekeduz_emre and Marina Kaymakcalan for their support.

https://t.co/eXLpP5mFdh

[Nazli Dizman @NazliDizman]

👀Whoat! A trivia #ASCO26? Who's in?
Love this idea! Looking forward to some friendly competition and team building while having fun through @oncology questions and fun facts! 🤓

🙋‍♀️See you at 2.30 pm at @ASCO TEC Lounge! @ASCOTECAG

#MedEd @OncMedEdCoP @vincedcataldo @IMG_Oncologists @OncoAlert @kor_shah @ja_ocejo @Noha_Soror @ASridharMD @FionnualaCrowle @thenasheffect @OncBrothers @TwoOncDocs @DrKarineTawagi @OncoAlert @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @jgong15 @DrSAHaddad @GIMedOnc @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc @montypal @neerajaiims @yekeduz_emre @DrYukselUrun @imdat_eroglu @hatice_bolek

[Giuseppe Banna @gbanna74]

Our new international real-world validation of the Meet-URO score in 1,418 first-line mRCC patients is out in @TOncologist.

Read here: https://t.co/EcfJgw6qqg

#OncTwitter #KidneyCancer #mRCC #PrecisionMedicine

[Hatice Bölek @hatice_bolek]

📣 Sac-TMT demonstrated improved OS and PFS compared with chemotherapy in advanced/recurrent endometrial cancer previously treated with platinum-based chemotherapy and anti-PD-1/L1 immunotherapy!

A new option in a setting with limited treatment options.

[Yüksel Ürün @DrYukselUrun]

Happy to see our work cited at APCCC.
ARPI selection in older patients is not only efficacy.
Drug interactions, comorbidities, and daily medications matter.
@hatice_bolek @yekeduz_emre @myESMO @ESMO_Open
@OncoAlert @APCCC_Lugano #APCCC26 @BourlonMaite @nataliagandur @Silke_Gillessen @AOmlin @CaPsurvivorship @NehaVapiwala @piet_ost

[Hatice Bölek @hatice_bolek]

@mcpinar Thank you Muharrem.

[Yüksel Ürün @DrYukselUrun]

Seeing your mentee featured by @myESMO is something else.
Dr. Hatice Bölek, top performers.
That’s the work paying off.
Proud. 🙌 @hatice_bolek @OncoAlert @Ankaratip1945 @AnkaraUni

[Hatice Bölek @hatice_bolek]

@DrYukselUrun @myESMO @OncoAlert @Ankaratip1945 @AnkaraUni Thank you 🙂. Grateful for your mentorship and for paving the way !

[Hatice Bölek @hatice_bolek]

Very happy to see this post by @myESMO.

[ESMO - Eur. Oncology @myESMO]

📣 Validate your expertise with #ESMOExamination 2026 — 24 Oct, 13:00–15:30 CEST.

📍Onsite in Madrid + selected locations.
⏳Early fee ends 28 Apr.
🔗 Secure your seat: https://t.co/08KgVZwrbW

[Hatice Bölek @hatice_bolek]

Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer @ASCO
https://t.co/qCi6xsjVcj

[Hatice Bölek @hatice_bolek]

The authors’ response: https://t.co/wX0jYC8gHq

[Hatice Bölek @hatice_bolek]

Our correspondence on the LUNAR trial is now published in JCO.
@DrYukselUrun @JCO_ASCO

https://t.co/YgbRiCJYTf

[Tom Powles @tompowles1]

Phase 3 LITESPARK-011: Belzutifan + Lenvatinib vs Cabozantinib in pretreated metastatic clear cell renal cancer #GU25 shows +ve PFS HR 0.75 , OS HR 0.85 (non-significant), ⬆️ RR 53% vs 40%, G3+ TRAEs 72% vs 66%. Cabozantinib is hard to beat making this a standard of care. Using the most active drugs first rather than sequencing is debatable, but not all patients can sequence. We still don’t have significant OS post in IO refractory RCC @OncoAlert

[Hatice Bölek @hatice_bolek]

An Editorial on a Clinical Grey Zone: cN+ M0 Bladder Cancer
Regional Node–positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings
https://t.co/qmUmrDXKQc
@EUplatinum @PGrivasMDPhD

[Yüksel Ürün @DrYukselUrun]

Huge congrats to brilliant mentees @hatice_bolek @coskunyazgann and mente/mentor @yekeduz_emre
Big thanks to @DrChoueiri @montypal @BradMcG04 and @DrRanaMcKay for their outstanding contributions, guidance, and support!
🔑IO rechallenge + VEGF TKI no survival gain in mRCC.
@OncJournal @OncoAlert @Ankaratip1945 @AnkaraUni @IKCCorg @kidneycan @KidneyCancer @Uromigos
https://t.co/UdQHPCaPdx

[Hatice Bölek @hatice_bolek]

@MuslihUrun Teşekkür ederim abi ☺️

[Hatice Bölek @hatice_bolek]

Happy to share that I passed the @myESMO Examination 2025 among the Top 5 performers and was included in the ESMO Exam Talent Pool 🎉

I would like to sincerely thank my mentors at @AUTF_DEKANLIK for their invaluable support throughout my education.

@DrYukselUrun @yekeduz_emre

[Yüksel Ürün @DrYukselUrun]

@hatice_bolek @myESMO @AUTF_DEKANLIK @yekeduz_emre Proud mentor moment.
Heartfelt congrats, Hatice!
This success is not luck.
The future is bright!
@myESMO @hatice_bolek @onkolojidernegi

[Hatice Bölek @hatice_bolek]

@DenizCanGuven1 @DrYukselUrun @yekeduz_emre Thank you for your kind words and for always supporting your juniors.

[Hatice Bölek @hatice_bolek]

It was a great experience to participate in the @myESMO Preceptorship on Prostate Cancer and to present a case in the session chaired by my mentor, @DrYukselUrun

If you haven’t attended before, you should definitely consider joining next year.

[Francesco Massari @fmassari79]

📢 Out now one of the largest real-world cohorts on adjuvant pembrolizumab for RCC by @aron_project

🔬 An important step forward in understanding how to optimize the management of renal cell carcinoma in real-life settings.

@IntKidneyCancer @OncoAlert @Uroweb